Archive | Redefining Early Stage Investments (RESI) RSS feed for this section

Introducing IPC Judges at RESI Boston June

1 Jun

By Momo Yamamoto, Investor Research Analyst, LSN

After announcing RESI Boston June’s IPC finalists last week, LSN is excited to announce our IPC judges! Our judges will be participating in 14 IPC sessions taking place all day on June 5th at the Westin Copley Place with 50+ companies pitching. Representing investment and industry experts of therapeutics, medical devices, diagnostics, and R&D and life science tools, IPC judges will hold a Q&A session following each pitch. Company poster boards will also be available to view at the RESI Exhibitor Hall, so don’t worry if you can’t attend a session! All registered attendees will receive “RESI Cash” to “invest” or vote for their favorite companies. The Top 3 companies with the most votes will be announced at the end of the day and will receive a prize along with a feature in the LSN newsletter!

Take a look below for to see who is judging!

Christopher Aleong
Managing Director, North America
BioEngine Capital

Jay Batchu

Alexandra Bause
Co-Founder & Venture Partner
Apollo Health Ventures

Rick Berenson
Director – Executive Board
Mass Medical Angels

Randy Berholtz
Senior Advisor
Mesa Verde Venture Partners

Kumar Bhargava
Managing Partner

Barri Blauvelt
Investment Advisor
Tamer Group

Karthik Bolisetty
Senior Associate
Gilde Healthcare Partners

Rebecca Brandes
Managing Director
Agilent Technologies

Lee Burnes
Senior Vice President, Global Research & Development
Avanos Medical

Jeffrey Champagne
Screening Committee
Boston Harbor Angels

Bruce Cohen
Venture Partner
Xeraya Capital

Alex de Winter
Vice President of New Ventures
Danaher Corporation

Ronald Dorenbos
Charles River Laboratories

Bettina Ernst

Marissa Fayer
U.S. Partner
Goddess Gaia Ventures

Justin Feng
Senior Associate
MRL Ventures Fund (MRLV)

Daniel Franke
M Ventures

Tom Gibbs
Debiopharm Innovation Fund

Tai Harada
Vice President
Fast Track Initiative

Michael Huang
Managing Partner
Taiwania Capital

Hanuman Jampani
Founder & President
Samrus International

Anil Jina
Executive in Residence
Iaso Ventures

Jennifer Jordan
Venture Partner
iGlobe Partners

Adam Kundzewicz
Executive Director
Boehringer Ingelheim Venture Fund

Seo Lee
SV Investment

Carla Lema Tomé
Search & Evaluation Lead
Spark Therapeutics

Jeffrey Moore
MP Healthcare Venture Management (MPH)

Ahmed Mousa
Business Development Executive
Tamer Group

Iris Ohrn
Investment Adviser
Business Region Goteborg

John Pennett
Angel Investor
Mid Atlantic Bio Angels

Jon Popke
Mid Atlantic Bio Angels

Kou Qin
Investment Principal
Eisai Inc.

Chandra Ramanathan
Global Head, Innovation Hubs
Danaher Corporation

Rachel Rath
Director, BARDA Alliance
Johnson & Johnson Innovation

Brock Reeve
CEO and Co-Founder
Eos BioInnovation

Jack Resnick
Inception Program Specialist
NVIDIA VC Alliance

Stephanie Rusinkiewicz
Sr. Manager of Business Development & Licensing, Surgical Innovation, Hernia & Wound Management

Sara Secall
Investment Director
Inveready Asset Management

Colin Sheehan
Associate Director, Ventures
Orange Grove Bio

Jill Sorensen
Chief Operating Officer
Medical Technology Enterprise Consortium (MTEC)

Avi Spier
Director, Strategic Alliances

Christopher Tan
Executive Director, Search & Evaluation, Business Development & Licensing, ID & Vaccines
Merck & Co., Inc.

Mark Tang
Managing Director
Good Health Capital

Wei Tao
Board Director & Chair, Bio/Genomics
Life Science Angels

Hung-Loi (Lloyd) Tran
Transpacific Venture Capital Partners

Jingjing Wang
Senior Associate
Lightstone Ventures

Tim Xu
Senior Director, Business Development, Search & Evaluation
Karuna Therapeutics


Stellar Content at RESI Boston June 5th, 2023

1 Jun

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

RESI is well-known for its vibrant partnering and high turnout of active investors, licensing partners and service providers focused on the early-stage life science community, but there is also an all-star line-up of quality educational content to help entrepreneurs on their fundraising journeys. Insightful investor panels will discuss key topics surrounding investment and partnership in specific areas of the life sciences and provide perspective on different investor types. There will also be live workshops focused on the most relevant issues that keep entrepreneurs up at night, imparted by experts in their fields.

Register for RESI for active partnering with a 3-day hybrid registration, or simply to partake in the amazing content being offered on June 5th with an Audience Access Pass. More Information Here

LSN NEW PRODUCT RELEASE – “Global Partnering Campaign (GPC), Fundraising & Licensing Partner Roadshow Management.”

Monday, June 5 | 8:00 – 8:30am ET; 12:00 – 12:30am ET

LSN will debut a leading-edge platform called the “Global Partnering Campaign (GPC), Fundraising & Licensing Partner Roadshow Management.” The GPC integrates LSN’s Investor and Licensing Partner Database and the Salesforce CRM.

Subscribing companies receive a vetted Global Target List (GTL) of likely partners garnered through one-on-one interviews with the LSN research team, which can be organized into three tiers of Investor Priority:

  • Tier 1: Partner is matched on a specific mandate.
  • Tier 2: Partner is matched on an opportunistic mandate seeking compelling technology assets.
  • Tier 3: Partner is matched as a potential fit based on past or recent actions. This is where the numbers game comes into play.

Information on these profiles is automatically updated daily, and user outreach and tasks can be tracked intuitively with CRM components, including the following:

  • Status of Outreach (Lead, Reviewing Materials, Call/Meeting Scheduled, etc.)
  • Materials Sent (Executive Summary, Pitch Deck, etc.)
  • Notes (NDA status, DD, and data room)
  • Reporting (investor/licensing pipeline)

LSN customized this platform, leveraging years of experience as a broker/dealer helping early-stage life sciences companies attract capital. Fundraising is a numbers game, and as companies transition from the regional to the global arena, difficulty juggling outreach with many different companies and contacts worldwide is inevitable. Managing your fundraising campaign adroitly is essential, and with the GPC platform, LSN makes it simple. The GPC product is a game changer for early-stage startups seeking between $100K and $50M (Seed-Series B).

Please join the GPC presentation on managing your global partnering campaign.


Karen Deyo, Director of Product, Israel BD, Life Science Nation

The NIH as a Technology Development and Commercialization Partner

Monday, June 5 | 9:00 – 9:50am ET

The National Institutes of Health (NIH) is a resource that companies should consider to bolster their pipeline or solve a development problem. Join us for a live webinar with representatives from various groups within the NIH for an opportunity to learn how your organization can partner with the NIH to get products to market. Participants will learn: • The NIH is more than basic research. Economic development is part of the mission. • That companies, entrepreneurs, and other buy-side stakeholders – not just academia – can partner with the NIH. • Why industry partnerships are mutually beneficial for companies and the NIH. • How companies have worked with the NIH (success stories and partnership examples). • Next steps – points of contact, partnering mechanisms, licensing.


  • Michael Salgaller, PhD, Supervisory Specialist, Technology Transfer Center, National Cancer Institute, National Institutes of Health (Moderator)
  • Tara L. Kirby, Ph.D., Director, Office of Technology Transfer, National Institutes of Health
  • Vladimir Popov, Ph.D., Chief Innovation Officer, Center for Innovation and Strategic Partnerships, Frederick National Laboratory for Cancer Research
  • Anthony D. Saleh, Ph.D., Chief Executive Officer and Founder, miRecule, Inc.

Tales from the Road

Monday, June 5 | 10:00 – 10:50am ET

The industry has quickly adapted to a “new normal” – entrepreneurs and investors meet virtually over digital platforms to discuss potential investment opportunities, and it is not uncommon to see entrepreneurs raise capital from investors they have never met before in person. That said, there is no doubt that the fundraising journey continues to be challenging for many. In this panel, you will be able to hear fellow entrepreneurs share their experiences, from successes to challenges. This panel will discuss the following topics and more: • What are some of the greatest challenges entrepreneurs have faced, especially during the pandemic, and how were they overcome? • How did entrepreneurs identify investors that fit their technology? • What are some misconceptions entrepreneurs had about the early-stage investment landscape? Furthermore, entrepreneurs will share unique tips and insights they have gained from their fundraising experiences, and how others can work their way towards a more successful campaign.


  • Greg Mannix, VP of International Business Development, Life Science Nation (Moderator)
  • Ross Bundy, Co-founder and CEO, CRISPR QC
  • Brian DellaValle, CEO, GLX Analytix
  • Robert Rioux, CEO, theraGI
  • Martha Shadan, Board Member, MedExecWomen

Negotiating Term Sheets

Monday, June 5 | 11:00 – 11:50am ET

This interactive workshop, organized and led by McDermott Will & Emery, will provide wisdom to early-stage CEOs and management on the latest trends in term sheets, with a focus on founder and management equity opportunities. The workshop will cover common issues of concern to entrepreneurs (valuation/dilution, liquidation preference, board makeup, protective provisions, anti-dilution). Experts from the legal, investment and entrepreneurial community will discuss the interplay of financing milestones in the term sheet discussion.


  • Mark Mihanovic, Partner, McDermott Will & Emery
  • Richard Smith, Counsel, McDermott Will & Emery
  • Nancy Briefs, President & CEO, AltrixBio, Inc.
  • Isaac Stoner, MBA, CEO, Octagon Therapeutics
  • Wasim Malik, Managing Partner, Iaso Ventures

IP Considerations for Start-ups

Monday, June 5 | 1:00 – 1:50pm ET

Intellectual Property is an absolutely key issue for life science startups to understand in order to make the right decisions along the journey toward commercialization. This session, led by Burns & Levinson Partner Shawn Foley, will address the main aspects of a good IP strategy that will help guide life science entrepreneurs be better prepared as they move their technologies forward.


Shawn P. Foley, Partner, Burns & Levinson

Maximizing Pre-Clinical Development Success for VC-Backed Start-Ups Through CRO Partnerships

Monday, June 5 | 2:00 – 2:50pm ET

Preclinical development is often complex and non-linear. You need to coordinate several CROs, CDMOs and an army of consultants while project managing it all. Join our workshop as we discuss best practices in finding and engaging with the right CRO partners to increase your chance of getting to IND faster, with greater success. Choosing the right CRO partner not only saves you time, money and whole lotta nerves, but gets the attention of investors. Investors appreciate well thought out, fully integrated product development plans that clearly identify value inflection milestones, contingencies, and mitigation strategies. The right CRO partner will make you look good in the eyes of investors—make sure to take advantage of that!


  • Marta New, PhD, MBA, CEO, Radyus Research
  • Omar Khalil, PhD, General Partner, Sante Ventures
  • Livija Deban, CSO, Prokarium Ltd
  • John Foglesong, MBA, CEO, Grannus Therapeutics
  • Paul Tebbey, PhD, MBA, Board Member & Advisor, Radyus Research

Fundraising Strategy and Messaging for First-Time CEOs

Monday, June 5 | 3:00 – 3:50pm ET

Join the Life Science Nation team to master the art of fundraising from Seed to Series B. Discover the essential insights and strategies to avoid common pitfalls and maximize your fundraising success. Learn about early-stage life science investors and uncover the 10 fundraising myths that can waste your time and hinder your progress. Additionally, we will share tips on Branding & Messaging, develop a strong brand identity and create high-quality collateral that engages potential investors. Communicate your message clearly and concisely to help investors decide quickly if you’re a potential fit. Gain the essential knowledge and skills to shape a strong fundraising strategy and increase your chances of securing the capital you need. This workshop is a must-attend for first-time CEOs and seasoned entrepreneurs seeking fundraising success.


  • Claire (Chae-Kyeong) Jeong, VP, Investor Research & Asia BD, Life Science Nation
  • Candice He, VP, Business Development & Global Investment Strategist, Life Science Nation

Company Valuation for Fundraising

Monday, June 5 | 4:00 – 4:50pm ET

Valuation is a key aspect of fundraising. An average value assumption for each company in a specific financing stage just does not do it anymore. For entrepreneurs, as for investors, its important to understand the value drivers of a company. We are looking at the financing trends of the last years, discuss dos and don’ts when speaking with investors and look at how to value a life science company with no revenues. Agenda: • Overview financing trends • Which is the right investor • Dos and don’ts • Company valuation approaches • Conclusion


  • Patrik Frei, Founder & CEO, Venture Valuation AG, Switzerland
  • Gergely Ivanyi, PharmD, Senior Consultant, Venture Valuation


Join LSN Team at Exciting Life Science Events Next Week!

1 Jun

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

Dear Life Science Nation Community,

We are thrilled to announce several upcoming events in the life science industry next week that are hosted by our close friend and partners. These events present excellent opportunities for networking, knowledge sharing, and collaboration. We invite you to join us and connect with like-minded professionals.

Here’s a list of the upcoming events:

  1. 2023 Enmore Biologics Development Summit
  1. Bullpen Networking Get-Together
  • Date: Monday, June 5, 2023
  • Time: 9:00 am – 12:00 pm EDT
  • Location: Howl at the Moon, 184 High Street, Boston
  • Event Link: Bullpen Networking Get-Together
  1. Burns & Levinson and JPM – Kick-Off Cocktail Party
  1. Bullpen Harbor Cruise
  • Date: Tuesday, June 6, 2023
  • Time: 7:00 pm – 10:00 pm EDT
  • Location: Boston Harbor Hotel
  • Event Link: Bullpen Harbor Cruise
  1. MWE Biobash
  • Date: Tuesday, June 6, 2023
  • Time: 7:00 pm – 10:00 pm EDT
  • Location: Moakley US Courthouse, Boston, MA
  • Event Link: MWE Biobash
  1. M2D2 Point of Care Showcase & Pitch Event
  1. Richi Entrepreneurs – Social Event

We look forward to meeting you at these exciting events. It’s an excellent opportunity to expand your network and stay updated with the latest developments in the life science industry. Don’t miss out on the chance to connect with fellow professionals and potential collaborators.

See you there!

Best regards,

The Life Science Nation Team


Hot Investor Mandate: Europe-Based Venture Group Investing Globally in Therapeutics, Open to All Modalities and Indications

1 Jun

The firm was founded in 2020 and is headquartered in Spain. Prior to being formally founded, the firm began as a support structure for an initial group of private investors interested in life sciences and grew into a platform that sources investment opportunities and represents several high net-worth individuals. The firm’s network invests globally in biotherapeutic companies from Seed to Series A and expects to participate in a limited number of later stage investments, following the capital allocation desires of the private investor network. The firm’s investors typically invest as a group, with check sizes ranging from 1 to 3 million USD with the intention to make up to three new investments per year.

The firm is focused on therapeutics but is modality and indication agnostic. This includes orphan diseases. Platform or multi-asset companies are often valued over single asset opportunities. Preferred stage of development varies based on the validation level of both the therapeutic target(s) and technology being applied. The more validated the targets and/or technology, the earlier the firm’s investor group is able to invest, including specific investment cases prior to pre-clinical animal efficacy.

The firm does not have specific management team requirements and has taken board seats in the past, however it is not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: Investor Group Looking to Make Impact Investments in Companies in All Sectors with Products Including a Core Technology Component

1 Jun

Founded in 2020, the firm is a group of Silicon Valley and India based ex-entrepreneurs and executives with operational experience and global networks investing in India’s next billion. The group focuses on impact investing, looking to help technology and health advance in India, especially serving the underprivileged communities. The four key areas of interest are healthcare, agritech, livelihood, and education-tech. The group is looking for companies in the Pre-Series A round with typical check sizes ranging from $125k-500k. The group looks at global companies.

The firm is sector-agnostic and is open to looking at any life science/healthcare startup with impactful technology, but it should have either a soft or hard-tech core component. The group is open to all stages and indications, however the firm does not look at orphan diseases.

The firm would like to see companies have 2-3 years of experience working with grant funding and passionate, resolute teams with 2+ years of proven commitment and strong market/technology expertise. Additionally, although companies are not required to relocate to India, they are required to clearly target at or involve India’s emerging and historically neglected populations of over 600 million and meeting a pressing need. The firm may take a board seat on a case-by-case basis as they act on both leading and co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: US and Asia Based Private Equity Firm Investing Opportunistically in Companies Looking to Enter the China Market

1 Jun

The firm was founded in 1996 and has offices in California, China and Taiwan. The firm is currently making investment from its USD 1.4B fund into promising private healthcare companies and from its $635M Opportunity Fund into promising public healthcare companies, invest in promising early-stage healthcare companies from its Innovation Fund. The firm invests exclusively in the healthcare sector; the firm invests primarily in the USA and Greater China but will also invest in other regions such as Europe and ASEAN countries. Within China, the firm makes growth investments in companies but also find some companies with interesting and innovative product in recent years there; in the USA and other regions, The firm makes both venture and growth-equity stage investments in both pre-revenue and revenue-stage companies. The firm’s allocations are highly varied. From the main fund, investments typically range from $20-50m, though larger investments are of interest as well; the Innovation Fund makes investments of typically $5-20 million. The firm is open to syndication. The firm is also particularly interested in working with companies that are open to or actively interested in seeking partnerships or opportunities in China.

The firm invests in therapeutics, medical devices, diagnostics, healthcare services, and clinically-oriented healthcare IT, and will consider investing in any indication area or technology subsector; however, orphan indications, dermatology/aesthetics, oncology, gene therapy, cell therapy, are of particular interest in the biopharma space; general surgery, neurovascular, cardiovascular, minimally invasive technologies, women’s health, respiratory care, novel diagnostics and orthopedics are of particular interest in the device space. Healthcare AI is an area they are interested and exploring. The Innovation Fund focuses on early-stage opportunities in biotech; from the main fund, the firm in most cases makes investments in products that have obtained market approval or are very close to commercialization, but earlier investments may be considered for highly innovative products or products that can demonstrate strong efficacy signals at an earlier stage (such as anti-infectives). For devices and diagnostics, the firm only invests in commercial-stage companies. Generally, the firm does not invest in imaging.

The firm is flexible regarding management teams and works with both serial entrepreneurs and entrepreneurs who lack industry experience. In addition to investing in private companies, the firm is able to invest in public companies by means of PIPEs or public market placements. The firm is interested in investing in companies with products that can demonstrate cost-effectiveness.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Hot Investor Mandate: East Coast Based Strategic Partner Looking to Invest in, License or Acquire Medical Device and Digital Health Technologies

1 Jun

The firm is a medical technology company based on the East Coast. The firm works with early-stage startups using a variety of structures including co-development, equity investments, licensing, and acquisitions (most common). In terms of equity investments, the $850M USD firm invests in companies from Series A to Series C (or later) with an average of $3-5M as the initial size of investment. In terms of acquisitions, the firm has done deals in the range of $10s to $100s of millions of dollars. The firm is interested in partnerships with breakthrough, disruptive technologies. The firm is a multi-stage investor and is interested in technologies worldwide.

The firm is interested in disruptive technologies that are strategically related to the company’s focus on digestive health and pain management. The firm is primarily interested in medical devices and digital health. Within medical devices, the firm is primary interested in 510K and De Novo’s and are open to PMA devices. The firm will consider working with companies at any stage of development. Within digital health, the firm is most interested in consumer facing products that are linked back to medical devices, and the associated data analytics around the products.

The firm primarily values a management team with technical experience as they are interested in promising disruptive technology. The firm also prefers a team with previous management experience. The firm acts as a strategic investor in equity investments. As a strategic investor, the firm will require board seating.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: